The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Miaowen LiuNachuan LuoZige FangQiangyun LiuFengming YiYiping WeiXinyi ZhangWenxiong ZhangPublished in: Journal of clinical pharmacy and therapeutics (2021)
For stage IIIB/IV nonsquamous NSCLC patients, maintenance therapy with Bev+Pem offers an increased survival outcome (PFS, OS) compared with monotherapy. However, the increased incidence of AEs should not be neglected.